Are there any subgroups of patients with advanced/metastatic NSCLC for whom you are using PD-1 inhibitors in the first-line setting, either alone or in combination with platinum-based chemotherapy?

With the advent of the 024 study pitting single agent Pembrolizumab vs standard chemotherapy in treatment-naive, advanced NSCLC showing a PFS and OS benefit in individuals whose tumors harbor high levels of PDL1 expression (> 50%), one can certainly make a strong case for testing all patients for PD...